| Name | Title | Contact Details |
|---|
Averion International Corporation is a Southborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Draeger Safety Pacific is a supplier of high quality respiratory protection, including single and dual filter masks as well as different material options to suit all customer requirements.
DTx Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Melbourne, FL. To find more information about DTx Inc., please visit www.dtx.com.
Healthy Directions publishes seven advisor-led newsletters. They are (in order of their first publication with us): Julian Whitaker, M.D.'s Health & Healing Stephen Sinatra, M.D.'s Heart, Health & Nutrition Dr.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.